摘要
肿瘤坏死因子相关的凋亡诱导配体(TRAIL)是肿瘤坏死因子超家族成员之一,能通过与死亡受体结合选择性诱导多种肿瘤细胞系的凋亡,而对正常细胞无明显影响,有望成为一种新的抗肿瘤制剂。介绍了TRAIL及其受体的诱导凋亡机制、开发现状及临床应用方面的研究进展。
Tumor necrosis factor（TNF）-related apoptosis-inducing ligand（TRAIL） is a member of TNF super family.Upon binding to its receptor,TRAIL selectively induces apoptosis in various cancer cell lines with little toxicity toward normal cells.This review introduces research progress on TRAIL,including its receptor,the induction pathway for apoptosis,the development progress,the current status for cancer treatment via targeting the TRAIL.
出处
《重庆理工大学学报（自然科学）》
CAS
2011年第2期47-52,67,共7页
Journal of Chongqing University of Technology：Natural Science
基金
重大新药研制"十一五"候选药物项目(20092X09103-682)
